| linagliptin / Generic mfg. |
ACTRN12615000732583: Stop or Replace: Effect of stopping sulfonylureas or replacing sulfonylureas with a dipeptidyl peptidase 4 (DPP-IV) inhibitor in Type 2 diabetes patients on pre-mix insulin. |
|
|
| Not yet recruiting | 4 | 99 | | | St Vincent's Hospital Sydney, St Vincent's Hospital Sydney, Competitive Grant from Regional Diabetes Support Scheme, Novo Nordisk | type 2 diabetes | | | | |
ChiCTR-IPR-15006340: Renal effects of Saxagliptin and Linagliptin in diabetic nephropathy: A randomized, double-blind, head to head study. |
|
|
| Not yet recruiting | 4 | 74 | | with Saxagliptin treatment ;with Linagliptin treatment | Tianjin Medical University; Level of the institution：, The National Natural Science General Program | Diabetic Nephropathy | | | | |
2013-000330-35: The impact on the blood sugar lowering drug Linagliptin and blood vessel function in patients with type 2 diabetes Der Einfluss der blutzuckersenkenden Substanz Linagliptin auf die Blutgefäßfunktion bei Patienten mit Typ 2 Diabetes |
|
|
| Ongoing | 4 | 50 | Europe | Trajenta (Linagliptin), Trajenta (Linagliptin) | Medizinische Universität Graz, Boehringer Ingelheim RCV GmbH & Co KG | Diabetes mellitus Type 2 Diabetes mellitus Typ 2 | | | | |
2015-002309-12: To compare gliclazide with linagliptin on the frequency of hypoglycaemia among patients with type II diabetes and chronic kidney disease stage 3b and 4. |
|
|
| Ongoing | 4 | 50 | Europe | Linagliptin, Gliclazide, Linagliptin, gliclazide, Linagliptin, gliclazide | Imperial College London, Joint Research Compliance Office, Boehringer Ingelheim Ltd. | Diabetes Mellitus and chronic kidney disease | | | | |
2015-005113-73: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes |
|
|
| Ongoing | 4 | 52 | Europe | Tablet, Capsule, Micardis, Jardiance, Trajenta, Vessel Due F | University Medical Center Groningen, UMCG | Type 2 diabetes with albuminuria, Type 2 diabetes with albumin in urine., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2015-005691-26: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes |
|
|
| Ongoing | 4 | 26 | Europe | Micardis, Jardiance, Trajenta, Vessel Due F | University Medical Center Groningen, University Medical Center Groningen | Type 1 diabetes with albuminuria, Type 1 diabetes with albumin in the urine, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-001977-18: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes |
|
|
| Ongoing | 4 | 26 | Europe | Micardis, Jardiance, Trajenta, Olumiant | University Medical Center Groningen, University Medical Center Groningen | Type 2 diabetes and albuminuria, Type 2 diabetes and albumin in the urine, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-004406-18: Geriatric outcomes among older Type 2 diabetic patients treated with DPP4inhibitors or glinides: focus on pro-inflammatory and oxidative stressmarkers (GOOD-WP1) Outcomes geriatrici in pazienti anziani affetti da diabete di tipo 2 trattaticon gli inibitori DPP4 o le glinidi: focus sui marcatori pro-infiammatori e distress ossidativo. |
|
|
| Not yet recruiting | 4 | 126 | Europe | TRAJENTA, Film-coated tablet, Tablet, TRAJENTA | IRCC INRCA, MINISTRY OF HEALTH | TYPE 2 DIABETES DIABETE DI TIPO 2, TYPE 2 DIABETES DIABETE DI TIPO 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-004663-12: Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors or glinides: focus on cognitive functioning (GOOD-WP3) Outcomes geriatrici in pazienti anziani affetti da diabete di tipo 2 trattati con gli inibitori DPP4 o le glinidi: focus sulla funzione cognitiva |
|
|
| Not yet recruiting | 4 | 146 | Europe | Novonorm, Trajenta, [NA], Tablet, Film-coated tablet, NOVONORM - 0.5 MG COMPRESSE-30 COMRESSE IN BLISTER, TRAJENTA - 5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 28 COMPRESSE | A.O.U. Università degli Studi della Campania "Luigi Vanvitelli", Ministero della Salute - Bando ricerca finalizzata - Italia | type 2 diabetes mellitus Diabete mellito di tipo 2, type 2 diabetes mellitus Diabete mellito di tipo 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Not yet recruiting | 4 | 100 | | Linagliptin ;HumalogMix50 | The General Hospital of Chinese People's Armed Police Forces; The General Hospital of Chinese People's Armed Police Forces, Self-financing | transplant recipient, diabetes | | | | |
2018-000359-42: Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors or glinides: focus on sarcopenia markers of muscle and physical performance status (GOOD-WP2) Outcome geriatrici in pazienti anziani affetti da diabete mellito tipo 2 trattati con inibitori DPP-4 o glinidi: focus sugli indicatori muscolari di sarcopenia e sullo stato di performance fisica (GOOD-WP2) |
|
|
| Not yet recruiting | 4 | 180 | Europe | Repaglinide, LINAGLIPTIN, [a10bx02], [a10bh05], Tablet, Film-coated tablet, NovoNorm 0,5mg, Trajenta 5mg | FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Ministero della Salute | Elderly patients suffering from type 2 diabetes mellitus in treatment with metformina Pazienti anziani affetti da diabete mellito di tipo 2 in terapia con metformina, Elderly patient suffering from type 2 diabetes mellitus Pazienti anziani affetti da diabete mellito di tipo 2, Diseases [C] - Hormonal diseases [C19] | | | | |
NCT05200793: Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome |
|
|
| Recruiting | 4 | 75 | RoW | Empagliflozin 25 mg, Empagliflozin, Linagliptin 10 mg, Linagliptin, Metformin 1500 mg, Metformin | Alexandria University | Polycystic Ovary Syndrome (PCOS) | 07/22 | 09/22 | | |
ChiCTR2000035887: A Randomized controlled trial for liraglutide plus linagliptin in improving neurological function of patients with acute ischemic stroke and hyperglycemia |
|
|
| Not yet recruiting | 4 | 680 | | Liraglutide plus Liraglutide ;Standard hypoglycemic therapy | Shanghai 6th People's Hospital; Shanghai 6th People's Hospital, Shanghai Shenkang Hospital Development Center | acute ischemic stroke | | | | |
NCT03194945: Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes |
|
|
| Completed | 4 | 412 | RoW | CSII followed by Lina+MET, CSII+Lina+Met, CSII followed by Lina, CSII+Lina, CSII followed by MET, CSII+Met, CSII alone, CSII | Sun Yat-sen University, The Seventh Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, The First Affiliated Hospital with Nanjing Medical University, Dongguan People's Hospital, Clifford Hospital, Guangzhou Panyu Central Hospital, Nanfang Hospital, Southern Medical University, Chinese PLA General Hospital, Peking University People's Hospital, Shanghai 10th People's Hospital, Shanghai Changzheng Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Huizhou Municipal Central Hospital | Type 2 Diabetes Mellitus | 12/22 | 12/22 | | |
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 600 | | DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin) | Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project | Type 2 diabetes | | | | |
ChiCTR2100049856: Effect and mechanism of polyethylene glycol Losenazeptide on cardiac microangiopathy in patients with type 2 diabetes mellitus complicated with massive albuminuria |
|
|
| Not yet recruiting | 4 | 100 | | Polyethylene Glycol Loxenatide injection ;Linagliptin Tablets | Tianjin Medical University Chu Hsien-l Memorial Hospital; Tianjin Medical University Chu Hsien-l Memorial Hospital, China International Medical Foundation Special Fund for International Diabetes Exchange and Practice “SenMei China Diabetes Research Fund” | type 2 diabetes mellitus | | | | |
HHTN, NCT06449833: Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD |
|
|
| Recruiting | 4 | 100 | RoW | Henagliflozein and Metformin, Linagliptin and Metformin | Zhujiang Hospital | Type2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease | 11/26 | 11/26 | | |
NCT06449235: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh |
|
|
| Not yet recruiting | 4 | 938 | RoW | Omarigliptin, Sulphonylureas, Metformin, Other DPP4-i, Thiazolidinediones, Alpha-Glucosidase Inhibitor, Glucagon-Like Peptide-1, Receptor Agonists (GLP1RA), SGLT2 inhibitors | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Pi Research and Development Center, Acme Laboratories Ltd. | Type2diabetes | 04/25 | 06/25 | | |
| Recruiting | 4 | 100 | Canada | Semaglutide Pen Injector, Ozempic, Wegovy | Canadian Medical and Surgical Knowledge Translation Research Group, Unity Health Toronto, Western University, Canada | Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity | 12/24 | 12/24 | | |
NCT06851962: Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes Clinical Trial |
|
|
| Not yet recruiting | 4 | 504 | Europe | Metformin, Dulaglutide, Semaglutide 1.0 mg, Empagliflozin (BI 10773), Canagliflozin, Dapagliflozin, pioglitazone, Sitagliptin, Vildagliptin (Galvus), linagliptin | Fundación para la Investigación del Hospital Clínico de Valencia | Diabetes Mellitus Type 2 | 06/26 | 07/26 | | |
ChiCTR2400089745: The efiicacy and safety of biweekly cofrogliptin versus daily linagliptin as add-on in Patients with Type 2 Diabetes Inadequately Controlled by Dual Therapy(metformin and dapagliflozin): A Multicenter, Randomized, Open-Label, Active-Controlled,non-inferiority trial |
|
|
| Not yet recruiting | 4 | 170 | | Triple combination therapy with cofrogliptin added to metformin and SGLT2i in type 2 diabetes mellitus (T2DM) patients who have inadequately controlled blood glucose despite adequate metformin and SGLT2i therapy for at least 12 weeks.; Triple combination therapy with linagliptin as active-control drug added to metformin and SGLT2i in type 2 diabetes mellitus (T2DM) patients who have inadequately controlled blood glucose despite adequate metformin and SGLT2i therapy for at least 12 weeks. | Tongji Hosptial Affiliated to Tongji Medical College of Huazhong University fo Science and Technology; Tongji Hosptial Affiliated to Tongji Medical College of Huazhong University fo Science and Technology, Haisco Pharmaceutical Group Co.,Ltd | Type 2 Diabetes Mellitus | | | | |
2013-000418-39: Early Prevention of Diabetes Complications in people with Pre-Diabetes in Europe Prevención temprana de complicaciones por diabetes en personas con pre-diabetes en Europa Wczesne zapobieganie powikłaniom cukrzycy u osób z tzw. stanem przedcukrzycowym w Europie |
|
|
| Ongoing | 3 | 2400 | Europe | GLUCOPHAGE/GLUCOPHAGE FORTE/DIANBEN/RISIDON 850mg film-coated tablet, Gluocophage 850 mg film-coated tablets, Trajenta 5 mg film-coated tablets, Jentadueto 2.5 mg/850 mg film-coated tablets, Gluocophage 850 mg film-coated tablets, Trajenta 5 mg film-coated tablets, Jentadueto 2.5 mg/850 mg film-coated tablets | FUNDACION DE INVESTIGACION EN RED EN ENFERMEDADES, FUNDACION DE INVESTIGACION EN RED EN ENFERMEDADES CARDIOVASCULARES (FIRCAVA), European Commission FP7 | Non diabetic hyperglycaemia:Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose (IFG) or both Hiperglucemia No Diabética:Intolerancia la Glucosa (ITG), Glucosa en ayuno alterada (GAA) o ambas | | | | |
NCT05641337: Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes |
|
|
| Recruiting | 3 | 184 | RoW | Insulin Degludec and Insulin Aspart, metformin, linagliptin | Huashan Hospital | Liver Cirrhosis, Diabetes | 12/25 | 12/25 | | |
DÁLIA, NCT05886088: Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 597 | RoW | LID104, Dapagliflozin, Linagliptin | EMS | Type 2 Diabetes Mellitus | 05/26 | 01/27 | | |
| Ongoing | 2 | 94 | Europe | Junuvia, Linagliptin, Teriparatide, Film-coated tablet, Solution for injection/infusion in pre-filled syringe, Januvia, Trajenta, Forsteo | Imperial College London | ischaemic cardiomyopathy, heart failure caused by heart attacks, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
DIASA3, NCT04662866: Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose |
|
|
| Recruiting | 2 | 64 | Europe | Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg, biguanide, glitazone, sodium glucose transport inhibitor, dipeptidyl peptidase inhibitor | Oslo University Hospital, The Research Council of Norway, Norwegian Diabetes Association, South-Eastern Norway Regional Health Authority, University of Oslo, University Hospital, Akershus, Vestre Viken Hospital Trust, University of Glasgow | Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders | 12/22 | 10/23 | | |
MORPHEUS-EC, NCT03281369 / 2016-004529-17: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) |
|
|
| Active, not recruiting | 1/2 | 410 | Europe, US, RoW | 5-Fluorouracil (5-FU), Leucovorin, Folinic acid, Oxaliplatin, Atezolizumab, Tecentriq, Cobimetinib, Cotellic, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab, RO7092284 | Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd. | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | 04/25 | 04/25 | | |
| Active, not recruiting | 1/2 | 314 | Europe, US, RoW | Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine, Linagliptin, Tocilizumab, Ipatasertib, Bevacizumab, Sacituzumab Govitecan, Radiation, Evolocumab, Tiragolumab, XL092, Zanzalintinib, Camonsertib | Hoffmann-La Roche | Carcinoma, Non-Small-Cell Lung | 09/25 | 11/26 | | |
|
NCT05729386: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions |
|
|
| Recruiting | 1 | 34 | RoW | GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2) | GC Biopharma Corp | Healthy Volunteers | 04/23 | 04/23 | | |
NCT05703984: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions |
|
|
| Recruiting | 1 | 50 | RoW | GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2) | GC Biopharma Corp | Healthy Volunteers | 04/23 | 04/23 | | |
NCT06243809: The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers |
|
|
| Not yet recruiting | 1 | 48 | NA | Linagliptin 5 mg Oral Tablet, Linagliptin, Trajenta 5 MG Oral Tablet | International Bio service | Healthy Volunteer | 05/24 | 07/24 | | |
| Enrolling by invitation | N/A | 30 | RoW | Biguanide, DPP4 inhibitors, SGLT2 inhibitors | Metabolic Research Unit | Abdominal Obesity, Type 2 Diabetes | 08/22 | 08/22 | | |
NCT02244164: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. |
|
|
| Terminated | N/A | 5 | Europe | Incretinomimetics, - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®)., DPP-4 inhibitors, - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®). | Erasme University Hospital | Type 2 Diabetes, Incretinomimetics, Pancreas | 02/23 | 02/23 | | |
NCT05768945: Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors |
|
|
| Active, not recruiting | N/A | 742670 | US | Semaglutide, DPP-4 inhibitor | Brigham and Women's Hospital, National Institute on Aging (NIA), Rutgers University, Johns Hopkins University | Diabetes | 07/23 | 12/23 | | |
NCT06570980: Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study. |
|
|
| Recruiting | N/A | 200 | RoW | sulfonylurease with metformin, DPP4 inhibitors with Metformin | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin | 08/24 | 08/24 | | |
NCT05347459: Cognitive Protective Effect of Newer Antidiabetic Drugs |
|
|
| Recruiting | N/A | 100 | RoW | Dapagliflozin, Empagliflozin, Canagliflozin, Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin | Alexandria University | Type 2 Diabetes | 12/23 | 12/23 | | |
| Completed | N/A | 1150 | Europe | SGLT-2i, DPP-4i | University of Campania "Luigi Vanvitelli" | Type 2 Diabetes Mellitus | 12/23 | 12/23 | | |
| Recruiting | N/A | 270000 | US | SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) | Kaiser Permanente, Geisinger Clinic, Henry Ford Health System, HealthPartners Institute, Patient-Centered Outcomes Research Institute | Type 2 Diabetes Mellitus, Cardiovascular Diseases | 12/24 | 08/25 | | |
| Recruiting | N/A | 550000 | US | DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU | Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute, Baylor College of Medicine, Baylor Scott and White Research Institute, The Cleveland Clinic, HealthCore, Inc., Humana Inc., Massachusetts General Hospital, Medical Outcomes Management, University of Iowa, Allina Health, Intermountain Health Care, Inc., Marshfield Clinic, Medical College of Wisconsin, University of Missouri-Columbia, University of Utah | Diabetes Mellitus, Type 2 | 06/24 | 06/24 | | |
NCT04853615: SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease? |
|
|
| Not yet recruiting | N/A | 800 | NA | Empagliflozin 25 MG, SGLT2 inhibitors | Fayoum University, Cairo University | SGLT2i Kideny Protection Against Contrast in Diabetic Kidney | 07/24 | 08/24 | | |
